GitHub

Multi-Level-Multi-Queue (MLMQ), a GPU-friendly data structure design to accelerate Single-Source Shortest Path (SSSP) on GPUs

The main code of MLMQ is in core, including the high-level templated framework and instantiated queues. SSSP is the SSSP program based on MLMQ, where users can specify the types of queues and their ...
Seeking Alpha

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist - Slideshow

The following slide deck was published by Structure Therapeutics Inc. in conjunction with this event.
BioSpace

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
about.fb

Expanding Our Data Center Community Action Grants Program

We’re currently accepting applications for the 2026 Data Center Community Action Grants program, and we’re expanding the grants to seven new communities. These grants provide direct funding to schools ...
Bloomberg L.P.

Using Data for Good: Program Launched to Help Singapore Charities Embrace the Power of Data

Eligible Singapore charities to get access to world-class expertise and funding through Bloomberg’s Data for Good Exchange (D4GX) program to boost data knowledge and capabilities. Six sector-leading ...
C&EN

Data-Independent Acquisition Coupled with Electron-Activated Dissociation for In-Depth Structure Elucidation of the Fatty Acid Ester of Hydroxy Fatty Acids

Graduate School of Pharmaceutical Sciences, Keio University, Minato-ku, Tokyo 105-8512, Japan Molecular and Cellular Epigenetics Laboratory, Graduate School of Medical Life Science, Yokohama City ...
Seeking Alpha

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...